151 related articles for article (PubMed ID: 22792051)
1. Development and validation of an RP-HPLC method for CB13 evaluation in several PLGA nanoparticle systems.
Alvarez-Fuentes J; Martín-Banderas L; Muñoz-Rubio I; Holgado MA; Fernández-Arévalo M
ScientificWorldJournal; 2012; 2012():737526. PubMed ID: 22792051
[TBL] [Abstract][Full Text] [Related]
2. Cannabinoid derivate-loaded PLGA nanocarriers for oral administration: formulation, characterization, and cytotoxicity studies.
Martín-Banderas L; Alvarez-Fuentes J; Durán-Lobato M; Prados J; Melguizo C; Fernández-Arévalo M; Holgado MÁ
Int J Nanomedicine; 2012; 7():5793-806. PubMed ID: 23209365
[TBL] [Abstract][Full Text] [Related]
3. Development and validation of a reversed-phase HPLC method for the quantification of paclitaxel in different PLGA nanocarriers.
Furman C; Carpentier R; Barczyk A; Chavatte P; Betbeder D; Lipka E
Electrophoresis; 2017 Oct; 38(19):2536-2541. PubMed ID: 28370074
[TBL] [Abstract][Full Text] [Related]
4. Single oral dose of cannabinoid derivate loaded PLGA nanocarriers relieves neuropathic pain for eleven days.
Berrocoso E; Rey-Brea R; Fernández-Arévalo M; Micó JA; Martín-Banderas L
Nanomedicine; 2017 Nov; 13(8):2623-2632. PubMed ID: 28756090
[TBL] [Abstract][Full Text] [Related]
5. Development and validation of RP-HPLC method for simultaneous estimation of docetaxel and ritonavir in PLGA nanoparticles.
Kumbhar PS; Diwate SK; Mali UG; Shinde TU; Disouza JI; Manjappa AS
Ann Pharm Fr; 2020 Sep; 78(5):398-407. PubMed ID: 32681903
[TBL] [Abstract][Full Text] [Related]
6. Development and validation of a rapid reversed-phase HPLC method for the determination of the non-nucleoside reverse transcriptase inhibitor dapivirine from polymeric nanoparticles.
das Neves J; Sarmento B; Amiji MM; Bahia MF
J Pharm Biomed Anal; 2010 Jun; 52(2):167-72. PubMed ID: 20117900
[TBL] [Abstract][Full Text] [Related]
7. Preparation and characterization of insulin-loaded bioadhesive PLGA nanoparticles for oral administration.
Zhang X; Sun M; Zheng A; Cao D; Bi Y; Sun J
Eur J Pharm Sci; 2012 Apr; 45(5):632-8. PubMed ID: 22248882
[TBL] [Abstract][Full Text] [Related]
8. HPLC-UV method development and validation for the quantification of ropinirole in new PLGA multiparticulate systems: Microspheres and nanoparticles.
Fuster J; Negro S; Salama A; Fernández-Carballido A; Marcianes P; Boeva L; Barcia E
Int J Pharm; 2015 Aug; 491(1-2):310-7. PubMed ID: 26149934
[TBL] [Abstract][Full Text] [Related]
9. Development and validation of a stability indicating isocratic HPLC method for gemcitabine with application to drug release from poly lactic-co-glycolic acid nanoparticles and enzymatic degradation studies.
Chen G; Svirskis D; Wen J
J Pharm Pharmacol; 2015 Nov; 67(11):1528-36. PubMed ID: 26369422
[TBL] [Abstract][Full Text] [Related]
10. Intranasal delivery of Huperzine A to the brain using lactoferrin-conjugated N-trimethylated chitosan surface-modified PLGA nanoparticles for treatment of Alzheimer's disease.
Meng Q; Wang A; Hua H; Jiang Y; Wang Y; Mu H; Wu Z; Sun K
Int J Nanomedicine; 2018; 13():705-718. PubMed ID: 29440896
[TBL] [Abstract][Full Text] [Related]
11. Optimization (central composite design) and validation of HPLC method for investigation of emtricitabine loaded poly(lactic-co-glycolic acid) nanoparticles: in vitro drug release and in vivo pharmacokinetic studies.
Singh G; Pai RS
ScientificWorldJournal; 2014; 2014():583090. PubMed ID: 24672337
[TBL] [Abstract][Full Text] [Related]
12. Preparation and in vitro evaluation of thienorphine-loaded PLGA nanoparticles.
Yang Y; Xie XY; Mei XG
Drug Deliv; 2016; 23(3):787-93. PubMed ID: 24870204
[TBL] [Abstract][Full Text] [Related]
13. Transferrin-conjugated lipid-coated PLGA nanoparticles for targeted delivery of aromatase inhibitor 7alpha-APTADD to breast cancer cells.
Zheng Y; Yu B; Weecharangsan W; Piao L; Darby M; Mao Y; Koynova R; Yang X; Li H; Xu S; Lee LJ; Sugimoto Y; Brueggemeier RW; Lee RJ
Int J Pharm; 2010 May; 390(2):234-41. PubMed ID: 20156537
[TBL] [Abstract][Full Text] [Related]
14. Understanding the quality of protein loaded PLGA nanoparticles variability by Plackett-Burman design.
Rahman Z; Zidan AS; Habib MJ; Khan MA
Int J Pharm; 2010 Apr; 389(1-2):186-94. PubMed ID: 20038446
[TBL] [Abstract][Full Text] [Related]
15. Colon-targeted delivery of cyclosporine A using dual-functional Eudragit
Naeem M; Bae J; Oshi MA; Kim MS; Moon HR; Lee BL; Im E; Jung Y; Yoo JW
Int J Nanomedicine; 2018; 13():1225-1240. PubMed ID: 29535519
[TBL] [Abstract][Full Text] [Related]
16. Insulin-loaded PLGA nanoparticles for oral administration: an in vitro physico-chemical characterization.
Santander-Ortega MJ; Bastos-González D; Ortega-Vinuesa JL; Alonso MJ
J Biomed Nanotechnol; 2009 Feb; 5(1):45-53. PubMed ID: 20055105
[TBL] [Abstract][Full Text] [Related]
17. Effects of polymer molecular weight on relative oral bioavailability of curcumin.
Tsai YM; Chang-Liao WL; Chien CF; Lin LC; Tsai TH
Int J Nanomedicine; 2012; 7():2957-66. PubMed ID: 22745556
[TBL] [Abstract][Full Text] [Related]
18. Preparation, characterization, and in vitro and in vivo investigation of chitosan-coated poly (d,l-lactide-co-glycolide) nanoparticles for intestinal delivery of exendin-4.
Wang M; Zhang Y; Feng J; Gu T; Dong Q; Yang X; Sun Y; Wu Y; Chen Y; Kong W
Int J Nanomedicine; 2013; 8():1141-54. PubMed ID: 23658482
[TBL] [Abstract][Full Text] [Related]
19. Development and validation of a rapid HPLC method for the quantification of GSE4 peptide in biodegradable PEI-PLGA nanoparticles.
Egusquiaguirre SP; Manguán-García C; Perona R; Pedraz JL; Hernández RM; Igartua M
J Chromatogr B Analyt Technol Biomed Life Sci; 2014 Dec; 972():95-101. PubMed ID: 25444543
[TBL] [Abstract][Full Text] [Related]
20. Cellular delivery of PEGylated PLGA nanoparticles.
Pamujula S; Hazari S; Bolden G; Graves RA; Chinta DD; Dash S; Kishore V; Mandal TK
J Pharm Pharmacol; 2012 Jan; 64(1):61-7. PubMed ID: 22150673
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
